The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Open accessAbstract
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS: We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes. RESULTS: Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06). CONCLUSIONS: Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although our analysis is secondary, reanalyses of clinical trial data have led to the detection of adverse events well after the market entry of major drugs such as rofecoxib and rosiglitazone. [36,37]”
From Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (2022) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In one study, 9 the use of rosiglitazone decreased the risk of diabetes in adults with impaired glucose tolerance by 62%; given concerns about cardiovascular safety, 14 however, the Food and Drug Administration has restricted the use of rosig litazone therapy to patients in whom glycemic control cannot be achieved with other medications and who cannot take pioglitazone.”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“a well-publicized meta-analysis of small phase 3 trials suggesting an increase in myocardial ischemic events (odds ratio, 1.43 [95% CI, 1.03–1.98])”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [210]
In the citing paper
“Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction (65,66) with rosiglitazone.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Self-citationEffect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.86.1.280 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,024
Orasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., & Plutzky, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.055 · Cited by 131
Ramracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128
Exercise therapy in Type 2 diabetes
Praet, S., & van Loon, L. J. C. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0129-0 · Cited by 135
Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease
Xu, A., & Vanhoutte, P. M. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00765.2011 · Cited by 130
Nuts, metabolic syndrome and diabetes
Kendall, C. W. C., Josse, A. R., Esfahani, A., & Jenkins, D. J. A. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510001546 · Cited by 127
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 128
Zhang, X., Zhu, Q., Chen, Y., Li, X., Chen, F., Huang, J., & Xu, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007165 · Cited by 130
Davidson, M., Meyer, P., Haffner, S. M., Feinstein, S. B., D’Agostino, R. B., Kondos, G. T., Pérez, A., Chen, Z., & Mazzone, T. (2008) · Circulation · doi:10.1161/circulationaha.107.746610 · Cited by 126
Update on diabetes mellitus: prevention, treatment, and association with oral diseases
Skamagas, M., Breen, T. L., & LeRoith, D. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01425.x · Cited by 130
Rosiglitazone and cardiotoxicity –weighing the evidence
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejme078117 · Cited by 126
Fang, F., Kang, Z., & Wong, C. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900119 · Cited by 126
The role of adipokines in skeletal muscle inflammation and insulin sensitivity
Nicholson, T. A., Church, C., Baker, D. J., & Jones, S. W. (2018) · Journal of Inflammation · doi:10.1186/s12950-018-0185-8 · Cited by 133
Ondrey, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0326 · Cited by 126
Drug-Metabolizing Enzyme and Transporter Expression in a Mouse Model of Diabetes and Obesity
Cheng, Q., Aleksunes, L. M., Manautou, J. E., Cherrington, N. J., Scheffer, G. L., Yamasaki, H., & Slitt, A. L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700114j · Cited by 125
SHRINE: Enabling Nationally Scalable Multi-Site Disease Studies
McMurry, A., Murphy, S., MacFadden, D., Weber, G., Simons, W. W., Orechia, J., Bickel, J. P., Wattanasin, N., Gilbert, C. A., Trevvett, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055811 · Cited by 134
Macrophage Polarization and Insulin Resistance: PPARγ in Control
Charo, I. F. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.006 · Cited by 129
Pagel-Langenickel, I., Bao, J., Joseph, J. J., Schwartz, D. R., Mantell, B. S., Xu, X., Raghavachari, N., & Sack, M. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800842200 · Cited by 124
Zhao, S., Kusminski, C. M., Elmquist, J. K., & Scherer, P. E. (2020) · Diabetes · doi:10.2337/dbi19-0018 · Cited by 130
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0090-3 · Cited by 123
Pioglitazone and Bladder Cancer
Tseng, C.-H. (2012) · Diabetes Care · doi:10.2337/dc11-1449 · Cited by 123
Bhansali, A. K., Asokumar, P., Walia, R., Bhansali, S., Gupta, V., Jain, A., Sachdeva, N. K., SHARMA, R. R., Marwaha, N., & Khandelwal, N. K. (2013) · Cell Transplantation · doi:10.3727/096368913x665576 · Cited by 123
Revisiting the Rosiglitazone Story — Lessons Learned
Rosen, C. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1008233 · Cited by 123
New Drugs for Type 2 Diabetes Mellitus
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 122
Ferguson, J. F., Allayee, H., Gerszten, R. E., Ideraabdullah, F., Kris‐Etherton, P. M., Ordovás, J. M., Rimm, E. B., Wang, T. J., & Bennett, B. J. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/hcg.0000000000000030 · Cited by 128
A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure
Wang, Y., Wang, Q., Li, C., Lu, L., Zhang, Q., Zhu, R., & Wang, W. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170925163427 · Cited by 123
INT131: A Selective Modulator of PPARγ
Motani, A. S., Wang, Z., Weiszmann, J., McGee, L. R., Lee, G., Liu, Q., Staunton, J., Fang, Z., Fuentes, H., Lindström, M., et al. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.025 · Cited by 125
Drug Insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal
Dunaif, A. E. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0787 · Cited by 122
Rosiglitazone: what went wrong?
Cohen, D. (2010) · BMJ · doi:10.1136/bmj.c4848 · Cited by 122
PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
Zolezzi, J. M., Santos, M. J., Candia, S. B., Pinto, C., Godoy, J. A., & Inestrosa, N. C. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12320 · Cited by 123
PPARs: the vasculature, inflammation and hypertension
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328325803b · Cited by 121
Empirical vs natural weighting in random effects meta‐analysis
Shuster, J. J. (2009) · Statistics in Medicine · doi:10.1002/sim.3607 · Cited by 122
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Composite End Points in Randomized Trials: There Is No Free Lunch
Tomlinson, G., & Detsky, A. S. (2010) · JAMA · doi:10.1001/jama.2009.2017 · Cited by 121
Human obesity and endothelium‐dependent responsiveness
Campia, U., Tesauro, M., & Cardillo, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01661.x · Cited by 124
Zhao, X., Gonzales, N. R., & Aronowski, J. A. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12350 · Cited by 122
Lee, E. S., Park, S., Kim, E., Yoon, Y. S., Ahn, H. Y., Park, C., Yun, Y. H., & Oh, S. W. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt087 · Cited by 121
Amato, A. A., Rajagopalan, S., Lin, J. Z., Carvalho, B. M., Figueira, A. C. M., Lu, J. Y.-L., Ayers, S. D., Mottin, M., Silveira, R. L., Souza, P. C. T., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.332106 · Cited by 126
The Record on Rosiglitazone and the Risk of Myocardial Infarction
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078116 · Cited by 119
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Zhu, J., Xu, Y., He, J., Yu, H., Huang, C., Gao, J., Dong, Q., Yao-xian, X., & Li, C. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2843 · Cited by 119
Tian, L., Cai, T. A., Pfeffer, M., Piankov, N., Crémieux, P., & Wei, L. (2008) · Biostatistics · doi:10.1093/biostatistics/kxn034 · Cited by 119
Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali, A. C., & BIA, M. J. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05081107 · Cited by 119
AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation
Daskalopoulos, E. P., Dufeys, C., Bertrand, L., Beauloye, C., & Horman, S. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.01.001 · Cited by 121
Inflammation and thrombosis in diabetes
Hess, K., & Grant, P. J. (2011) · Thrombosis and Haemostasis · doi:10.1160/ths10-11-0739 · Cited by 117
Diabesity: therapeutic options
Colagiuri, S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01182.x · Cited by 121
The effects of old, new and emerging medicines on metabolic aberrations in PCOS
Bargiota, Α., & Diamanti‐Kandarakis, E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812437355 · Cited by 120
Si, M., Lou, J.-S., Zhou, C., Shen, J.-N., Wu, H., Yang, B., He, Q., & Wu, H. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.12.044 · Cited by 119
New Drugs for the Treatment of Diabetes Mellitus
McGuire, D. K., & Inzucchi, S. E. (2008) · Circulation · doi:10.1161/circulationaha.107.704080 · Cited by 118
Lichen Planopilaris Treated With a Peroxisome Proliferator–Activated Receptor γ Agonist
Mirmirani, P. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.283 · Cited by 117
Anti-hyperglycemic and hypolipidemic effects of Cistanche tubulosa in type 2 diabetic db/db mice
Xiong, W.-T., Gu, L., Wang, C., Sun, H., & Liu, X. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.09.027 · Cited by 117
Marsh, S. A., Dell’Italia, L. J., & Chatham, J. C. (2010) · Amino Acids · doi:10.1007/s00726-010-0699-8 · Cited by 118
Review article: diagnosis and treatment of non‐alcoholic fatty liver disease
OH, M. K., Winn, J., & Poordad, F. F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03752.x · Cited by 120
Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017
Wilkinson, S., Douglas, I., Stirnadel-Farrant, H. A., Fogarty, D. G., Pokrajac, A., Smeeth, L. L., & Tomlinson, L. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022768 · Cited by 116
Thiazolidinedione Drugs and Cardiovascular Risks
Kaul, S., Bolger, A. F., Herrington, D. M., Giugliano, R. P., & Eckel, R. H. (2010) · Circulation · doi:10.1161/cir.0b013e3181d34114 · Cited by 121
The Metabolic Syndrome—from Insulin Resistance to Obesity and Diabetes
Gallagher, E. J., LeRoith, D., & Karnieli, E. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.05.002 · Cited by 118
Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives
Virally, M., Blickle, J., Girard, J. R., Halimi, S., Simon, D., & Guillausseau, P.-J. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.07.001 · Cited by 122
Xu, Y., Yu, T., Ma, G., Zheng, L., Jiang, X., Yang, F., Wang, Z., Li, N., He, Z., Song, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62556 · Cited by 110
The pathogenesis and treatment of cardiac atrophy in cancer cachexia
Murphy, K. T. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00720.2015 · Cited by 115
Assessing the Cardiovascular Safety of Diabetes Therapies
Goldfine, A. B. (2008) · New England Journal of Medicine · doi:10.1056/nejmp0805758 · Cited by 114
Pai, V., Paneerselvam, A., Mukhopadhyay, S., Bhansali, A. K., Kamath, D., Shankar, V., Gambhire, D., Jani, R. H., Joshi, S., & Patel, P. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813518680 · Cited by 119
PPARγ and its ligands: therapeutic implications in cardiovascular disease
Villacorta, L., Schopfer, F. J., Zhang, J., Freeman, B. Α., & Chen, Y. (2009) · Clinical Science · doi:10.1042/cs20080195 · Cited by 115
Biscetti, F., Gaetani, E., Flex, A., Aprahamian, T. R., Hopkins, T. A., Straface, G., Pecorini, G., Stigliano, E., Smith, R. C., Angelini, F., et al. (2008) · Diabetes · doi:10.2337/db07-0765 · Cited by 115
Winkelmayer, W. C., Setoguchi, S., Levin, R., & Solomon, D. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2368 · Cited by 115
Ginsenoside Rb1 promotes browning through regulation of PPARγ in 3T3-L1 adipocytes
Mu, Q., Fang, X., Li, X., Zhao, D., Mo, F., Jiang, G., Yu, N., Zhang, Y., Guo, Y., Fu, M., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.064 · Cited by 114
The Vulnerable Atherosclerotic Plaque: Scope of the Literature
Alsheikh-Ali, A. A. A., Kitsios, G. D., Balk, E. M., Lau, J. W. Y., & Ip, S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-6-201009210-00272 · Cited by 115
Effects of Dapagliflozin on Cardiovascular Risk Factors
Ptaszynska, A., Hardy, E., JOHNSSON, E. K., Parikh, S. J., & List, J. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2667 · Cited by 115
Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone
Tornio, A., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018010 · Cited by 114
The pharmacological management of metabolic syndrome
Larsen, J. R., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 121
Alam, F., Islam, M. A., Mohamed, M., Ahmad, I., Kamal, M. A., Donnelly, R., IDRIS, I. R., & Gan, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41854-2 · Cited by 117
Review: Stroke prevention: modifying risk factors
Romero, J. R., Morris, J. G., & Pikula, A. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708093847 · Cited by 119
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Douglas, I., Evans, S. J. W., Pocock, S., & Smeeth, L. L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000154 · Cited by 112
Gøtzsche, P. C., & Johansen, H. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007851.pub3 · Cited by 113
Targeting white, brown and perivascular adipose tissue in atherosclerosis development
van Dam, A. D., Boon, M. R., Berbée, J. F. P., Rensen, P. C. N., & van Harmelen, V. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.051 · Cited by 120
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 122
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 117
Sinha, B., & Ghosal, S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.014 · Cited by 117
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., Block, C. E. M. D., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 124
Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis
Rücker, G., & Schumacher, M. C. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-34 · Cited by 117
The Glycemic Index: Physiological Significance
Esfahani, A., Wong, J. M., Mirrahimi, A., Srichaikul, K., Jenkins, D. J. A., & Kendall, C. W. C. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10718109 · Cited by 123
Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C. M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2011) · Experimental Diabetes Research · doi:10.1155/2011/215764 · Cited by 112
Glucokinase activators in diabetes management
Coghlan, M. P., & Leighton, B. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.145 · Cited by 115
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 126
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 116
Liang, C., Ren, Y., Tan, H., He, Z., Jiang, Q., Wu, J., Zhen, Y., Fan, M., & Wu, Z. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00450.x · Cited by 111
Challenges of Translating Basic Research Into Therapeutics: Resveratrol as an Example
Smoliga, J. M., Vang, O., & Baur, J. A. (2011) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr062 · Cited by 113
Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.024 · Cited by 110
Zizzo, G., & Cohen, P. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0081-4 · Cited by 94
Cai, T., Parast, L. M., & RYAN, L. M. (2010) · Statistics in Medicine · doi:10.1002/sim.3964 · Cited by 115
Diabetes Treatment, Part 2: Oral Agents for Glycemic Management
Fowler, M. J. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.4.131 · Cited by 112
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., DeMets, D., George, J. T., Gerstein, H. C., Hobbs, T. M., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 111
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R. S., & Zinman, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0873-z · Cited by 110
Thiazolidinediones as anti‐inflammatory and anti‐atherogenic agents
Ceriello, A. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.790 · Cited by 110
Cytokine Dysregulation in Chronic Kidney Disease: How Can We Treat It?
Carrero, J. J., Yılmaz, M. İ., Lindholm, B., & Stenvinkel, P. (2008) · Blood Purification · doi:10.1159/000126926 · Cited by 110
Coronary heart disease outcomes in patients receiving antidiabetic agents
McAfee, A. T., Koro, C. E., Landon, J. E., Ziyadeh, N. J., & Walker, A. M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1443 · Cited by 108
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
Mallewa, J. E., Wilkins, E., Vilar, J., Mallewa, M., Doran, D. A., Back, D. J., & Pirmohamed, M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn251 · Cited by 109
Diabetic nephropathy: landmark clinical trials and tribulations
Chan, G. C. W., & Tang, S. C. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu411 · Cited by 109
Anti-Diabetic Effect of Portulaca oleracea L. Polysaccharideandits Mechanism in Diabetic Rats
Bai, Y., Zang, X., Ma, J., & Xu, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081201 · Cited by 109
Shuster, J. J., Jones, L. S., & Salmon, D. A. (2007) · Statistics in Medicine · doi:10.1002/sim.3060 · Cited by 105
Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients
McInnes, G. T., Evans, M., Prato, S. D., Stümvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., & Kothny, W. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12548 · Cited by 111
Genetically Modified Pig Models for Human Diseases
Fan, N., & Lai, L. (2013) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2012.07.014 · Cited by 107
Metadata
- Authors
- Nissen, S. E., & Wolski, K.
- Affiliations
- Cleveland Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2457-2471
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127125241
- Semantic Scholar
- 238422dc26dc6a78cb2b03fad835d7d1f1f95edb
- Cited by
- 4,675
- References
- 29
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 89 · 2023: 117 · 2022: 132 · 2021: 169 · 2020: 175 · 2019: 198 · 2018: 213 · 2017: 222 · 2016: 234 · 2015: 218 · 2014: 259 · 2013: 271 · 2012: 295
- FWCI
- 395.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- New England Journal of Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, myocardial infarction, cardiovascular mortality, type 2 diabetes, thiazolidinediones, drug safety, HbA1c
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Middle Aged, Myocardial Infarction, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
